4. Ness TJ, Jones L, Smith H. Use of compounded topical analgesics- results of an Internet survey. Reg Anesth Pain Med 2002; 27: 309-12.
5. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57: 1331-46.
6. Durand C, Alhammad A, Willett KC. Practical considerations for optimal transdermal drug delivery. Am J Health Syst Pharm 2012; 69: 116-24.
7. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-38.
8. Stanos SP. Topical agents for the management of musculoskeletal pain. J Pain Symptom Manage 2007; 33: 342-55.
10. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006; 13: 175-87.
11. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs 1998; 56: 783-99.
12. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 2010; 99: 21-50.
13. Van Hal DA, Jeremiasse E, Junginger HE, Spies F, Bouwstra JA. Structure of fully hydrated human stratum corneum: a freeze-fracture electron microscopy study. J Invest Dermatol 1996; 106: 89-95.
14. Moss GP, Dearden JC, Patel H, Cronin MT. Quantitative structure-permeability relationships (QSPRs) for percutaneous absorption. Toxicol In Vitro 2002; 16: 299-317.
16. Franckum J, Ramsay D, Das NG, Das SK. Pluronic lecithin organogel for local delivery of anti-inflammatory drugs. Int J Pharm Compd 2004; 8: 101-5.
17. Assandri A, Canali S, Giachetti C. Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster. Drugs Exp Clin Res 1993; 19: 89-95.
18. Keppel Hesselink JM, Kopsky DJ, Bhaskar AK. Skin matters! The role of keratinocytes in nociception: a rational argument for the development of topical analgesics. J Pain Res 2017; 10: 1-8.
20. Zhao P, Barr TP, Hou Q, Dib-Hajj SD, Black JA, Albrecht PJ, et al. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain 2008; 139: 90-105.
21. Hejnol A, Rentzsch F. Neural nets. Curr Biol 2015; 25: R782-6.
22. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000; 60: 555-74.
23. Rolf C, Engström B, Beauchard C, Jacobs LD, Le Liboux A. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999; 38: 564-7.
25. Rodriguez-Merchan EC. Topical therapies for knee osteoarthritis. Postgrad Med 2018; 130: 607-12.
26. Derry S, Wiffen PJ, Kalso EA, Bell RF, Aldington D, Phillips T, et al. Topical analgesics for acute and chronic pain in adults- an overview of cochrane reviews. Cochrane Database Syst Rev 2017; 5: CD008609.
29. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85: S3-14.
30. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151-8.
31. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61: 914-8.
33. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. Curr Med Res Opin 2004; 20 Suppl 2: S13-9.
34. Lee W, Hahn K, Hur J, Kim Y. Effect of topical lidocaine patch on postoperative pain management in laparoscopic appendectomy: a randomized, double-blind, prospective study. J Laparoendosc Adv Surg Tech A 2018; 28: 1061-7.
35. Lau LL, Li CY, Lee A, Chan SK. The use of 5% lidocaine medicated plaster for acute postoperative pain after gynecological surgery: a pilot randomized controlled feasibility trial. Medicine 2018; 97: e12582.
36. Habib AS, Polascik TJ, Weizer AZ, White WD, Moul JW, ElGasim MA, et al. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesth Analg 2009; 108: 1950-3.
38. Campbell BJ, Rowbotham M, Davies PS, Jacob P, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with postherpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002; 91: 1343-50.
40. ZTlido--a new lidocaine patch for postherpetic neuralgia. Med Lett Drugs Ther 2019; 61: 41-3.
43. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs 2004; 13: 1445-56.
44. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013; 2: CD007393.
45. Smith H, Brooks JR. Capsaicin-based therapies for pain control. Prog Drug Res 2014; 68: 129-46.
46. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998; 21: 531-43.
48. Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 2007; 148: 560-72.
51. Bley K. Effects of topical capsaicin on cutaneous innervation: implications for pain management. Open Pain J 2013; 6: 81-94.
52. Pershing LK, Reilly CA, Corlett JL, Crouch DJ. Effects of vehicle on the uptake and elimination kinetics of capsaicinoids in human skin in vivo. Toxicol Appl Pharmacol 2004; 200: 73-81.
53. Chaiyasit K, Khovidhunkit W, Wittayalertpanya S. Pharmacokinetic and the effect of capsaicin in capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai 2009; 92: 108-13.
54. England J, Wagner T, Kern KU, Roth-Daniek A, Sell A. The capsaicin 8% patch for peripheral neuropathic pain. Br J Nurs 2011; 20: 926-31.
55. Knezevic NN, Tverdohleb T, Nikibin F, Knezevic I, Candido KD. Management of chronic neuropathic pain with single and compounded topical analgesics. Pain Manag 2017; 7: 537-58.
56. Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg 2014; 119: 170-8.
57. Gordh T, Karlsten R, Kristensen J. Intervention with spinal NMDA, adenosine, and NO systems for pain modulation. Ann Med 1995; 27: 229-34.
58. Tekelioglu UY, Apuhan T, Akkaya A, Demirhan A, Yildiz I, Simsek T, et al. Comparison of topical tramadol and ketamine in pain treatment after tonsillectomy. Paediatr Anaesth 2013; 23: 496-501.
59. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain 2009; 146: 18-25.
61. Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 2011; 4: 7107.
62. Berrazueta JR, Losada A, Poveda J, Ochoteco A, Riestra A, Salas E, et al. Successful treatment of shoulder pain syndrome due to supraspinatus tendinitis with transdermal nitroglycerin. A double blind study. Pain 1996; 66: 63-7.
64. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev 2003; 55: 1-20.
66. Hiom S, Patel GK, Newcombe RG, Khot S, Martin C. Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin. Br J Dermatol 2015; 173: 300-2.
68. Ong J, Kerr DI. Recent advances in GABAB receptors: from pharmacology to molecular biology. Acta Pharmacol Sin 2000; 21: 111-23.
69. Kopsky DJ, Keppel Hesselink JM. Neuropathic pain as a result of acromegaly, treated with topical baclofen cream. J Pain Symptom Manage 2013; 46: e4-5.
72. Rashidi F, Sehhati F, Ghojazadeh M, Javadzadeh Y, Haghsaie M. The effect of phenytoin cream in comparison with betadine solution on episiotomy pain of primiparous women. J Caring Sci 2012; 1: 61-5.
73. Hesselink JM, Kopsky DJ. Topical phenytoin cream reduces burning pain due to small fiber neuropathy in sarcoidosis. J Anesth Pain Med 2017; 2: 1-3.
74. Graham T, Grocott P, Probst S, Wanklyn S, Dawson J, Gethin G. How are topical opioids used to manage painful cutaneous lesions in palliative care? A critical review. Pain 2013; 154: 1920-8.
75. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003; 105: 303-8.
76. Szallasi A. Vanilloid (capsaicin) receptors in health and disease. Am J Clin Pathol 2002; 118: 110-21.
77. Robbins W. Clinical applications of capsaicinoids. Clin J Pain 2000; 16: S86-9.
78. Kárai LJ, Russell JT, Iadarola MJ, Oláh Z. Vanilloid receptor 1 regulates multiple calcium compartments and contributes to Ca
2+-induced Ca
2+ release in sensory neurons. J Biol Chem 2004; 279: 16377-87.
80. Wiley RG, Lappi DA. Targeted toxins in pain. Adv Drug Deliv Rev 2003; 55: 1043-54.